Applying nanoparticle delivery systems to overcome treatment obstacles (toxicities, bioavailability, resistance) in solid tumors; Using nanoparticle delivery systems to treat genetic bone malformation
T32 Fellowship, National Institute of Health F31 Fellowship
After I graduated with an honors double major in Biochemistry and Biology with a concentration in Cell, Molecular, and Genetics at the University of Delaware in 2014, I continued my research career at Weill Cornell Medical College by joining the Pharmacology Ph.D. program. My research experience during university at the USDA and at Nemours Children’s Hospital strengthened my interest in translational medical research, leading me to join Dr. Daniel Heller’s Cancer Nanomedicine Lab at Memorial Sloan Kettering Cancer Center. I have developed nanoparticle drug delivery systems to improve the treatment of lung, breast, liver, skin, and other solid tumors by altering drug localization. I am also collaborating with Dr. Greenblatt’s lab at Weill Cornell, and we are applying our nanoparticle system to target therapeutics to the bone growth plate in genetically abnormal bone growth models. Working with Dr. Heller has allowed me to gain experience drafting patents and organizing material transfer agreements, writing grants, and collaborating with scientists across institutions, locally and internationally. The translational nature of our work also allows me insight into the process of developing our technology for clinical application. Going forward, I am interested in bringing my knowledge of chemistry and drug delivery, in vitro and in vivo models, and pharmacology to bear in projects that push translational research forward.